Science Source-linked briefing

Rumi Therapeutics signs deal with Enthorin for fragile X program

Rumi Therapeutics, part of Rumi Scientific Holdings, has announced an option to license agreement with Enthorin Therapeutics LLC to advance RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor,…

Bioworld Science Desk

Original contributor via Bioworld

| October 28, 2026 | 1 min read | Updated Oct 29, 1:00 AM

Rumi Therapeutics signs deal with Enthorin for fragile X program — Image supplied with the source report: Bioworld.

Rumi Therapeutics, part of Rumi Scientific Holdings, has announced an option to license agreement with Enthorin Therapeutics LLC to advance RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor,…

Rumi Therapeutics, part of Rumi Scientific Holdings, has announced an option to license agreement with Enthorin Therapeutics LLC to advance RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor, for the treatment of fragile X syndrome.

Source disclosure

This is a source-linked briefing. Read the original report from Bioworld .